Recombinant MVA Virus Boosting HIV CD8+ T Cell Immunity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current HIV vaccines often fail to induce strong cell-mediated immunity and broadly reactive anti-envelope antibodies, and using the same recombinant viral vector for both prime and boost can lead to diminished immune responses due to preexisting immunity.

Innovation Solution

A pharmaceutical composition comprising a recombinant MVA virus expressing HIV env, gag, and pol genes, with modifications to encode gp120 and the membrane-spanning and ectodomain of gp41, and a pharmaceutically acceptable carrier, used for boosting a CD8+ T cell immune response primed by a DNA vaccine, while eliciting an antibody response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If the same recombinant viral vector is used for both prime and boost vaccination, then the vaccination process is simplified, but the immune response is diminished due to preexisting immunity

Engineering Contradiction:

Improvevaccination process simplicityVSAvoidimmune response strength

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The vaccination strategy is segmented into two distinct phases: a DNA prime phase followed by an MVA boost phase. This segmentation allows each vector type to perform its optimal function without interference from preexisting immunity to the same vector, thereby maintaining strong immune responses while simplifying the overall vaccination protocol compared to multiple different vector approaches.

Inventive Principle:

Principle #1Segmentation

2Adaptability or versatility

If plasmid DNA vaccination is used to induce both humoral and cellular immune responses, then both T and B cell responses are activated, but the protection against pathogenic HIV-1 is insufficient

Engineering Contradiction:

Improveimmune response breadthVSAvoidprotection efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The DNA vaccine serves as a preliminary action that primes the immune system by introducing HIV-1 antigens and activating both T and B cell responses. This preliminary priming establishes a foundation of immune recognition that is then significantly enhanced and consolidated by the subsequent MVA boost, which provides stronger cellular immunity and broader protective efficacy against pathogenic HIV-1.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS9453239B2Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes

Publication Date: 2016.09.27 EMORY UNIVERSITY

AI summary

The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.